BRIEF-4 SC receives funding from Eurostars programme for further research of its anti-cancer agents with an epigenetic mode of action. The three-year research programme in cooperation with two other European epigenetics companies will carry out additional preclinical research on its clinical epigenetic agents resminostat and 4sc-202, investigating aspects such as immunomodulator potential. Read more on Reuters
from EUROPA - Syndicated Research News Feed http://ift.tt/1TUvc0m
via IFTTT
No comments:
Post a Comment